Safety of Topical OLEOZON® in the Treatment of Tinea Pedis: Phase IV Clinical Trial


* Ozone Research Center; Havana, Cuba
** Molecular Pharmacology, Ancona University; Ancona, Italy
*** "Dr Carlos J. Finlay" Hospital; Havana, Cuba
**** FINE, Military Hospital; Cárdenas, Matanzas, Cuba
***** "Dr Agostinho Neto" General Hospital; Guantánamo, Cuba

Key words: ozonized vegetable oils, phase IV clinical trial, safety, tinea pedis, adverse drug reactions, Oleozon®

SUMMARY - The efficacy of topical OLEOZON® against tinea pedis has already been demonstrated. The aim of the present study was to assess the adverse reactions associated with topical OLEOZON® in patients with tinea pedis. A multicenter, open, phase IV clinical trial was carried out. An adverse drug reaction report form specifying the reactions most commonly associated with topical OLEOZON® was designed. This study lasted three years. Patients were treated with topical OLEOZON® twice a day for six weeks. Of the total of 2596 patients admitted to the study, 2165 (83.4%) patients finished the treatment. The main cause of drop out of the 431 patients (16.6%), was the scant attendance at the clinical evaluation. Six patients (0.3%) showed adverse reactions. The most frequently reported adverse reactions were skin burning sensation, pruritus and erythema of mild intensity. Skin burning sensation was considered, according to the causal relationship, as definite; pruritus and erythema were considered probable. Taking into account the number of patients that finished the treatment, an efficacy of 92.7% (2007 patients cured) was achieved. The favourable safety profile achieved with topical OLEOZON® in this study, together with its demonstrated efficacy and its low cost justify the extension of this treatment in clinical practice for patients with tinea pedis, particularly in developing countries.

Introduction

Tinea pedis is a very common and often chronic foot infection caused by fungi of the genera Trichophyton, Microsporum or Epidermophyton 1-3. Topical and oral OLEOZON® (ozonized sunflower oil) is a medication produced in Cuba which has been evaluated previously in different clinical trials 4-7. It is already registered for the treatment of tinea pedis, impetigo and giardiasis. Its remarkable germicidal action has been well documented 8-10, as well as its lack of toxicity and low cost 11-13.

Topical OLEOZON® was evaluated in a controlled randomized phase III assay, using ketoconazole (Nizoral®) as the comparing group 4. The results demonstrated that no significant differences were found between the two medications, nor were any side-effects or bacterial superinfection observed in the study.

Adequate safety profiles for tinea pedis treatment were observed in different clinical trials 14-16, as for topical OLEOZON® 4, but it was not known whether a similar profile would be found in routine clinical practice conditions using a large number of patients. Therefore, taking into account the characteristics of OLEOZON® and the need to find effective, low-cost safe antimycotic drugs, the aim of this study was to perform a multicenter open phase IV clinical assay to evaluate the true picture of adverse drug reactions (ADRs) and the drug’s effectiveness in routine clinical practice.

Patients and Methods

A multicenter, open, phase IV clinical assay was carried out aimed at evaluating the possible ADRs during the treatment of patients with tinea pedis using topical OLEOZON®. An ADR report form, specifying the reactions most commonly associated with OLEOZON® was designed. This study lasted three years. Four hospitals from different provinces of Cuba participated. All the patients were clinically (presence of maceration, desquamation, fissures, erythema, vesicles and/or pruritus) and mycologically (positive culture of skin scrapings of the affected areas in Sabouraud glucose agar-chloramphenicol) diagnosed as suffering from tinea...
pedis. They were aged over 15 years, of either gender and any race and without previous treatment or with more than five days without any topical or systemic medication. From the study were excluded patients with decompensated diseases, hypersensitivity to the medication and those being treated with antibiotics, corticoids, cytostatics or immunodepressant drugs.

Treatment

Patients were treated with topical OLEOZON® (each 100 ml contains 8-12 % hydroperoxides of unsaturated triglycerides as active oxygen 17,18), twice per day, for six weeks.

ADR Evaluation

An ADR is defined as any noxious and undesired effect to a drug observed at doses usually administered therapeutically in humans. The severity of ADR was classified in four levels: 1) Mild, when the side-effect did not significantly interfere with the normal functions of the patient, no therapy was necessary; 2) Moderate, when the side-effect produced an impairment of the normal functions of the patient, without being a risk to his/her health, but needed specific treatment; 3) Severe, when the side-effect produced a significant impairment of the normal functions of the patient, without being a risk to his/her life, but needed hospitalization; 4) Very severe, if a reaction was potentially life-threatening or contributed to the patient’s death.

A qualitative assessment was used to classify the causal relationship as definite, probable, possible or doubtful 19. A reaction was classified as definite if it had the criteria (A), followed a reasonable temporal sequence after drug administration; (B) followed a known pattern of response to the suspected drug; (C) could not be explained by concurrent disease or other drugs; and (D) was confirmed by improvement upon removal of the drug and by reappearance on rechallenge. It was considered probable if it had the criteria (A), (B), (C) and was confirmed on suspension of the drug but not on rechallenge.

Results

In this study, the mean value of the evolution time of the disease was 60 months with five relapses per year. The mean age was 35 years, 85% were male and 55% were white. Interdigital lesions were the most common symptom in more than 90%; the plantar lesion was present in less than 50% of cases.

A total of 2596 patients suffering from tinea pedis were included in this study, but only 2165 patients (83.4%) finished the treatment because 431 (16.6%) dropped out due to scant attendance at the clinical evaluation (every 2 weeks). Taking into account the number of patients that finished
the topical OLEOZON® treatment, an efficacy of 92.7% (2007 patients cured) was achieved and only 7.3% (158 patients) were not cured (figure 1). However, if we consider as failure the number of patients that abandoned the treatment the effectiveness decreases to 77.3% (analysis by intention to treat). Only six patients (0.3%) presented ADRs. The most frequently reported ADRs were skin burning sensation, pruritus and erythema of mild intensity. Four patients presented skin burning sensation, one patient presented skin burning sensation and pruritus and the other one also had skin burning sensation but with erythema. Once the ADRs appeared in these six patients, the treatment was suspended for 24h. Patients were evaluated during this period to confirm their improvement upon removal of OLEOZON® and the reappearance or not of the ADRs on rechallenge. Skin burning sensation was considered definite according to the causal relationship; pruritus and erythema were considered probable. No causal relationship considered as possible or doubtful was found in this study (table 1).

Considering the number of patients that finished the treatment, a major incidence (50.1%) of the scaly form of tinea pedia, followed by the macerated form (31.9%), were present in this study. The scaly and macerated forms demonstrated a high percentage of cured patients, with 97.9 and 94.9%, respectively (table 2).

No relapses were found in six months of follow-up.
Discussion

The results of this study suggest that topical OLEOZON® is a safe drug with an excellent post-marketing safety profile. Post-marketing monitoring is an important procedure to detect reactions that can become apparent only when the drug is used in a large and varied population. Indeed, those observed in clinical trials for tinea pedis do not reflect the true behaviour of ADRs due to the limited number of patients.

Active surveillance provides a vital service to the healthcare system by identifying and assessing early warning signals, and when appropriate, taking preventive action to minimize the deleterious effects of drugs. In Cuba this has a special relevance because the information generated in clinical trials can be limited by the patients' recruitment rate.

The most frequent ADRs associated with topical OLEOZON® therapy were skin-burning sensation, pruritus and erythema. These ADRs had also been reported in the treatment of impetigo with topical OLEOZON® in a phase III clinical trial carried out in 136 children. However, some contradictions are present with respect to ADRs. In the study, no ADRs were reported with the use of topical OLEOZON® in adults with different diseases (tinea pedis, pyoderma, onycomycosis, simplex herpes). Also, another study (unpublished observations) carried out in 80 children with impetigo reported no ADRs. In this study only 0.3% of ADRs were found.

Skin burning sensation could be a consequence of topical OLEOZON® application, due to the active metabolites that are formed (aldehydes, acids, ozonides and hydroperoxides) in the reaction of the ozone with the sunflower oil and the patient's sensitivity. For that reason, skin burning sensation can be classified as definite, according to the causal relationship, however, erythema and pruritus were in the group of probable ADRs (confirmed on suspension of the drug but not on rechallenge).

A high efficacy (92.7%) was obtained when all the patients that finished the treatment are considered. However, with respect to the analysis by intention to treat, where all the patients included in the study are considered, the effectiveness decreased to 77.3%, similar to that obtained in the phase III clinical trial. This is an important point to take into account, since in daily practice patients sometimes interrupt treatment, this result being a truer figure of medication efficacy. The incidence in respect to the different clinical forms, is similar to that already reported, where the scaly form occupied the first on the list. Also, the scaly form responds best to different treatments.

Another aspect to highlight is that topical OLEOZON® exhibits an antifungal and antibacterial activity as well as an anti-inflammatory property. Normally, the severity of tinea pedis infection determines the course of treatment required. Mild infections may be resolved using a topical agent, but are commonly associated with high relapse rates. However, more severe cases (eg, dermatophytosis complex) may require oral and topical treatment that eliminates the bacterial and fungal infection and sometimes if inflammation is present an agent with a known anti-inflammatory action may be needed. All these drugs can be accompanied by side-effects such as gastrointestinal distress, headache, and hepatic toxicity, among others. In our study, the mean value of the evolution time of the disease was 60 months with five relapses per year, then, we can consider that we are studying chronic patients. This six weeks topical OLEOZON® treatment guaranteed the absence of relapses (at least in the six months of follow-up), and the presence of superinfection due to bacteria and the associated inflammation. In this case OLEOZON® will be the best choice due to its germicidal and anti-inflammatory properties, its low cost, safety and tolerability (favourable cost/benefit ratio).

Conclusions

The favourable safety profile achieved with topical OLEOZON® in this study together with its demonstrated efficacy and low cost justify the extension of this treatment in clinical practice for patients with tinea pedis, particularly in developing countries.

Acknowledgements

This study was sponsored by the Ozone Research Center and the Health Ministry of Cuba.


Dr S ilvia M enéndez Cepero
C entro N acional de I nvestigaciones C ientíficas
C entro de I nvestigaciones del Ozono
P O Box 914, P laya
H abana, C uba
T el.: +53 7 271 9264
F ax: +53 7 208 0497
E -mail: silviamenendez@infomed.sld.cu